HK1112024A1 - Polypeptide having an improved cytosine deaminase activity - Google Patents

Polypeptide having an improved cytosine deaminase activity

Info

Publication number
HK1112024A1
HK1112024A1 HK08107021.0A HK08107021A HK1112024A1 HK 1112024 A1 HK1112024 A1 HK 1112024A1 HK 08107021 A HK08107021 A HK 08107021A HK 1112024 A1 HK1112024 A1 HK 1112024A1
Authority
HK
Hong Kong
Prior art keywords
polypeptide
cytosine deaminase
deaminase activity
improved
activity
Prior art date
Application number
HK08107021.0A
Other languages
English (en)
Inventor
Philippe Erbs
Original Assignee
Transgene Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Transgene Sa filed Critical Transgene Sa
Publication of HK1112024A1 publication Critical patent/HK1112024A1/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/78Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • A61P31/22Antivirals for DNA viruses for herpes viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62DNA sequences coding for fusion proteins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HK08107021.0A 2003-07-21 2006-06-02 Polypeptide having an improved cytosine deaminase activity HK1112024A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP03360087 2003-07-21
US50827403P 2003-10-06 2003-10-06
HK06106361A HK1084150A1 (en) 2003-07-21 2006-06-02 Polypeptide having an improved cytosine deaminase activity

Publications (1)

Publication Number Publication Date
HK1112024A1 true HK1112024A1 (en) 2008-08-22

Family

ID=39719832

Family Applications (2)

Application Number Title Priority Date Filing Date
HK08107021.0A HK1112024A1 (en) 2003-07-21 2006-06-02 Polypeptide having an improved cytosine deaminase activity
HK06106361A HK1084150A1 (en) 2003-07-21 2006-06-02 Polypeptide having an improved cytosine deaminase activity

Family Applications After (1)

Application Number Title Priority Date Filing Date
HK06106361A HK1084150A1 (en) 2003-07-21 2006-06-02 Polypeptide having an improved cytosine deaminase activity

Country Status (17)

Country Link
US (3) US7790445B2 (ko)
EP (2) EP1897938B9 (ko)
JP (1) JP4672659B2 (ko)
KR (1) KR101062140B1 (ko)
CN (1) CN1826410B (ko)
AT (1) ATE405654T1 (ko)
AU (1) AU2004257935B2 (ko)
CA (1) CA2532783C (ko)
CY (1) CY1110397T1 (ko)
DE (1) DE602004015995D1 (ko)
DK (1) DK1649023T3 (ko)
ES (1) ES2311831T3 (ko)
HK (2) HK1112024A1 (ko)
IL (1) IL173158A (ko)
PL (1) PL1649023T3 (ko)
PT (1) PT1649023E (ko)
WO (1) WO2005007857A1 (ko)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2489486C2 (ru) 2006-06-20 2013-08-10 Трансжене С.А. Процесс получения поксвирусов и композиции поксвирусов
US8357531B2 (en) 2007-07-03 2013-01-22 Transgene S.A. Immortalized avian cell lines
CN101688182A (zh) 2007-07-03 2010-03-31 特兰斯吉恩股份有限公司 永生化禽细胞系
EP3502256A3 (en) * 2008-09-26 2019-09-25 Tocagen Inc. Recombinant vectors
US8445270B2 (en) 2009-05-12 2013-05-21 Transgene S.A. Immortalized avian cell lines and use thereof
IN2012DN01577A (ko) 2009-07-21 2015-06-05 Transgene Sa
EP2527432A1 (en) * 2011-05-23 2012-11-28 Novozymes A/S Bi-directional cytosine deaminase-encoding selection marker
WO2013004658A1 (en) 2011-07-01 2013-01-10 Transgene Sa Formulations of 5-fluorocytosine and uses thereof.
US9642921B2 (en) 2012-12-20 2017-05-09 Tocagen Inc. Cancer combination therapy and recombinant vectors
DK3129037T3 (da) 2014-04-10 2020-02-03 Transgene Onkolytiske koppevirusvektorer
WO2016008976A1 (en) 2014-07-16 2016-01-21 Transgene Sa Oncolytic virus for expression of immune checkpoint modulators
JP6655618B2 (ja) 2014-12-01 2020-02-26 トランジェーヌTransgene 安定な液体ワクシニアウイルス処方物
EP3256156A1 (en) * 2015-02-13 2017-12-20 Transgene SA Immunotherapeutic vaccine and antibody combination therapy
CA3023022A1 (en) 2016-05-04 2017-11-09 Transgene Sa Combination therapy with cpg tlr9 ligand
US20190336552A1 (en) 2016-05-30 2019-11-07 Astellas Pharma Inc. Genetically engineered vaccinia viruses
US10888594B2 (en) * 2016-05-30 2021-01-12 National University Corporation Tottori University Genetically engineered vaccinia viruses
WO2018091680A1 (en) 2016-11-18 2018-05-24 Transgene Sa Cowpox-based oncolytic vectors
WO2019020543A1 (en) 2017-07-28 2019-01-31 Transgene Sa ONCOLYTIC VIRUSES EXPRESSING AGENTS TARGETING METABOLIC IMMUNE MODULATORS
MX2020009262A (es) 2018-03-07 2021-01-08 Transgene Vectores de parapoxvirus.
WO2020011754A1 (en) 2018-07-09 2020-01-16 Transgene Chimeric vaccinia viruses
JP7484717B2 (ja) 2018-09-26 2024-05-16 アステラス製薬株式会社 腫瘍溶解性ワクシニアウイルスと免疫チェックポイント阻害剤との併用によるがん療法並びにこれに用いるための医薬組成物及び組合せ医薬
WO2023213764A1 (en) 2022-05-02 2023-11-09 Transgene Fusion polypeptide comprising an anti-pd-l1 sdab and a member of the tnfsf
WO2023213763A1 (en) 2022-05-02 2023-11-09 Transgene Poxvirus encoding a binding agent comprising an anti- pd-l1 sdab
TW202413636A (zh) 2022-08-18 2024-04-01 法商傳斯堅公司 嵌合痘病毒

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4603112A (en) 1981-12-24 1986-07-29 Health Research, Incorporated Modified vaccinia virus
FR2583429B1 (fr) 1985-06-18 1989-11-03 Transgene Sa Vecteur d'expression de l'interferon u dans les cellules de mammifere, procede pour sa mise en oeuvre et produit obtenu et composition pharmaceutique contenant l'interferon u
CA2018273C (en) 1989-06-09 1999-04-06 Peter D. Senter Thermally stable cytosine deaminase
US5358866A (en) 1991-07-03 1994-10-25 The United States Of America As Represented By The Department Of Health And Human Services Cytosine deaminase negative selection system for gene transfer techniques and therapies
DK0931830T3 (da) 1993-02-16 2001-06-11 Onyx Pharma Inc Cytopatiske vira til terapi og profylakse af neoplasi
EP0804590A1 (en) * 1993-05-21 1997-11-05 Targeted Genetics Corporation Bifunctional selectable fusion genes based on the cytosine deaminase (cd) gene
FR2705686B1 (fr) 1993-05-28 1995-08-18 Transgene Sa Nouveaux adénovirus défectifs et lignées de complémentation correspondantes.
FR2722208B1 (fr) 1994-07-05 1996-10-04 Inst Nat Sante Rech Med Nouveau site interne d'entree des ribosomes, vecteur le contenant et utilisation therapeutique
US5856153A (en) 1994-11-17 1999-01-05 Cayla Suicide genes and new associations of pyrimidine nucleobase and nucleoside analogs with new suicide genes for gene therapy of acquired diseases
FR2727689A1 (fr) 1994-12-01 1996-06-07 Transgene Sa Nouveau procede de preparation d'un vecteur viral
FR2737222B1 (fr) 1995-07-24 1997-10-17 Transgene Sa Nouveaux vecteurs viraux et lignee pour la therapie genique
FR2759382A1 (fr) 1997-02-10 1998-08-14 Transgene Sa Nouveaux composes et compositions les contenant utilisables pour le transfert d'au moins une substance therapeutiquement active, notamment un polynucleotide, dans une cellule cible et utilisation en therapie genique
FR2762615B1 (fr) 1997-04-28 1999-07-16 Inst Nat Sante Rech Med Nouveau site interne d'entree des ribosomes et vecteur le contenant
FR2777570A1 (fr) * 1998-04-17 1999-10-22 Transgene Sa Mutant ayant une activite phosphoribosyl transferase
US6552005B1 (en) * 1998-09-29 2003-04-22 Uab Research Foundation Molecular chemotherapy enhancement of radiotherapy
US20030121068A1 (en) 2001-11-30 2003-06-26 Paul Orchard Vector encoding suicide and marker constructs
US7141404B2 (en) 2002-12-27 2006-11-28 Onyx Pharmaceuticals, Inc. Candida kefyr cytosine deaminase

Also Published As

Publication number Publication date
IL173158A0 (en) 2006-06-11
AU2004257935A1 (en) 2005-01-27
ES2311831T3 (es) 2009-02-16
US8226954B2 (en) 2012-07-24
DK1649023T3 (da) 2008-10-06
CA2532783C (en) 2013-09-17
KR20060040697A (ko) 2006-05-10
JP2006527994A (ja) 2006-12-14
JP4672659B2 (ja) 2011-04-20
US8257692B2 (en) 2012-09-04
CN1826410B (zh) 2011-10-26
EP1897938B1 (en) 2010-10-06
ATE405654T1 (de) 2008-09-15
KR101062140B1 (ko) 2011-09-05
CA2532783A1 (en) 2005-01-27
US20100330031A1 (en) 2010-12-30
US20100330051A1 (en) 2010-12-30
EP1897938A1 (en) 2008-03-12
US20070264235A1 (en) 2007-11-15
PT1649023E (pt) 2008-11-20
WO2005007857A1 (en) 2005-01-27
US7790445B2 (en) 2010-09-07
PL1649023T3 (pl) 2009-01-30
EP1649023A1 (en) 2006-04-26
EP1897938B9 (en) 2011-08-31
EP1649023B1 (en) 2008-08-20
AU2004257935B2 (en) 2009-11-19
IL173158A (en) 2009-12-24
CY1110397T1 (el) 2015-04-29
DE602004015995D1 (de) 2008-10-02
CN1826410A (zh) 2006-08-30
HK1084150A1 (en) 2006-07-21

Similar Documents

Publication Publication Date Title
HK1084150A1 (en) Polypeptide having an improved cytosine deaminase activity
IN2014CN02050A (ko)
BRPI0517493A (pt) polinucleotìdeo isolado, promotor vetor de expressão, célula hospedeira e uso de um polinucleotìdeo
BR0308946A (pt) Gene que codifica a acetolactato sintase
DE60215534D1 (de) Antimikrobielle polypeptide aus pseudoplectania nigrella
DK1601776T3 (da) Ekspressionsvektorer omfattende mCmV-IE2-promotoren
ATE462000T1 (de) Verfahren zur herstellung von l-arginin, l- ornithin oder l-citrullin
GB0711424D0 (en) Recombinant transferrin mutants
TW200734350A (en) Polypeptides having antimicrobial activity and polynucleotides encoding same
TW200700076A (en) Polypeptides having antimicrobial activity and polynucleotides encoding same
DE50213015D1 (de) Lipase-varianten
SG146640A1 (en) Isolated photoprotein mtclytin, and use thereof
TW200621285A (en) Polypeptides having antimicrobial activity and polyncleotides encoding same
TW200510460A (en) Antimicrobial polypeptides
TW200502253A (en) Antimicrobial polypeptides
WO2006031993A3 (en) Enhancing recombinant hemoglobin production by co-expression with alpha hemoglobin stabilizing protein
ATE496121T1 (de) Lactobacillus fermentum n-desoxyribosyl- transferasen und deren verwendung zur enzymatischen synthese von 2',3'- didesoxynucleosiden und 2',3'-didehydro-2',3'- didesoxynucleosiden
HK1082510A1 (en) Promoter to il-18bp, its preparation and use
TW200617021A (en) Isolated photoprotein aequorin y89f, and its use
DE60330140D1 (de) Gen-silencing-vektor und diesen verwendendes gen-silencing-verfahren
TW200716177A (en) Isolated photoprotein aqdecay, and its use
GB2441941A (en) An isolated recombinant vaccinia virus complement control protein (HRVCP) polypeptide
WO2003099995A3 (en) Murine ortholog of the human disrupted-in-schizophrenia 1 gene
DK1780275T3 (da) Polypeptid med en delta5-fedtsyre-desaturationsaktivitet, polynukleotid kodende for polypeptidet og anvendelse deraf
TW200716666A (en) Isolated photoprotein gr-bolinopsin, and its use

Legal Events

Date Code Title Description
AM Amended specification (according sect 146 of patent law)

Free format text: CORRECTION OF THE PRIORITY COUNTRY CODE FROM EM TO EP.

Effective date: 20090505